230 related articles for article (PubMed ID: 27994509)
1. MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1.
Zhang Y; Xu W; Ni P; Li A; Zhou J; Xu S
Int J Biol Sci; 2016; 12(12):1437-1447. PubMed ID: 27994509
[TBL] [Abstract][Full Text] [Related]
2. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
3. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2.
Wang T; Ge G; Ding Y; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Chin Med J (Engl); 2014; 127(12):2357-62. PubMed ID: 24931256
[TBL] [Abstract][Full Text] [Related]
4. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
5. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells.
Jiang T; Dong P; Li L; Ma X; Xu P; Zhu H; Wang Y; Yang B; Liu K; Liu J; Xue J; Lv R; Su P; Kong G; Chang Y; Zhao C; Wang L
Oncol Rep; 2017 Jul; 38(1):151-158. PubMed ID: 28534959
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
8. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.
Ge X; Liu X; Lin F; Li P; Liu K; Geng R; Dai C; Lin Y; Tang W; Wu Z; Chang J; Lu J; Li J
Oncotarget; 2016 Apr; 7(17):24466-82. PubMed ID: 27016414
[TBL] [Abstract][Full Text] [Related]
10. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway.
Chen Z; Gao YJ; Hou RZ; Ding DY; Song DF; Wang DY; Feng Y
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):171-180. PubMed ID: 30657558
[TBL] [Abstract][Full Text] [Related]
12. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2.
Wen L; Cheng F; Zhou Y; Yin C
Saudi J Gastroenterol; 2015; 21(5):313-9. PubMed ID: 26458859
[TBL] [Abstract][Full Text] [Related]
13. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2.
Zhuang M; Shi Q; Zhang X; Ding Y; Shan L; Shan X; Qian J; Zhou X; Huang Z; Zhu W; Ding Y; Cheng W; Liu P; Shu Y
Tumour Biol; 2015 Apr; 36(4):2737-45. PubMed ID: 25492481
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.
Zhu W; Shan X; Wang T; Shu Y; Liu P
Int J Cancer; 2010 Dec; 127(11):2520-9. PubMed ID: 20162574
[TBL] [Abstract][Full Text] [Related]
16. MiR-99a suppresses cell migration and invasion by regulating IGF1R in gastric cancer.
Xu XL; Guo AX; Pan QY; Chang AL; Zhao CR
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7375-7382. PubMed ID: 31539124
[TBL] [Abstract][Full Text] [Related]
17. Upregulated miR-132 in Lgr5
Zhang L; Guo X; Zhang D; Fan Y; Qin L; Dong S; Zhang L
Mol Carcinog; 2017 Sep; 56(9):2022-2034. PubMed ID: 28383763
[TBL] [Abstract][Full Text] [Related]
18. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp.
Lu C; Shan Z; Li C; Yang L
Biomed Pharmacother; 2017 Feb; 86():450-456. PubMed ID: 28012924
[TBL] [Abstract][Full Text] [Related]
19. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9.
Wang J; Xue X; Hong H; Qin M; Zhou J; Sun Q; Liang H; Gao L
Oncotarget; 2017 Jan; 8(1):574-582. PubMed ID: 27880941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
